Home > Boards > US Listed > Biotechs > Agios Pharmaceuticals, Inc. (AGIO)

AGIO $47.39

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ClearlyStocks Member Profile
 
Followed By 565
Posts 40,762
Boards Moderated 2
Alias Born 06/08/06
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/14/2019 4:22:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 4:08:48 PM
Agios to Present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019 GlobeNewswire Inc. - 6/10/2019 1:12:44 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/5/2019 4:09:33 PM
Agios Announces the Planned Retirement of Chief Scientific Officer, Scott Biller, Ph.D., Effective December 31, 2019 GlobeNewswire Inc. - 6/5/2019 4:00:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/3/2019 4:03:11 PM
Agios Presents Updated Data from Phase 1 Studies of TIBSOVO® (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant... GlobeNewswire Inc. - 6/3/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/31/2019 4:10:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/31/2019 4:10:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/31/2019 4:09:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/31/2019 4:08:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/31/2019 4:06:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/31/2019 4:06:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/31/2019 4:05:25 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/31/2019 4:04:27 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/15/2019 4:27:19 PM
Agios to Present Clinical Data from its IDH Program at ASCO GlobeNewswire Inc. - 5/15/2019 4:05:00 PM
Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously T... GlobeNewswire Inc. - 5/15/2019 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/2/2019 3:25:05 PM
Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adu... GlobeNewswire Inc. - 5/2/2019 1:18:47 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/2/2019 8:59:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/2/2019 7:26:07 AM
Agios Reports Business Highlights and First Quarter 2019 Financial Results GlobeNewswire Inc. - 5/2/2019 7:00:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 4/26/2019 11:48:48 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 4/26/2019 11:10:09 AM
ClearlyStocks   Wednesday, 09/07/16 11:11:13 AM
Re: None
Post # of 46 
AGIO $47.39

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist